Combination of HSP90 inhibitor onalespib with crizotinib to treat or delay resistance in NSCLC: Preclinical and clinical investigations

Date 02 March 2015
Event 13th International Congress on Targeted Anticancer Therapies
Session Phase 1 studies: Miscellaneous drugs & targets
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Non-Small-Cell Lung Cancer, Metastatic
Presenter Harold Keer